Use access key #2 to skip to page content.
$2.10 0.00 (0.00%)
5/2/2008 4:00 PM

Renovis, Inc. (RNVS)

CAPS Rating:
**

The Company is a science-driven, biopharmaceutical company that seeks to discover, develop, and commercialize therapeutics for major medical needs in the areas of neurological and inflammatory diseases.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

RNVS doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

34 Outperforms
11 Underperforms
 

All-Stars

7 Outperforms
7 Underperforms
 

Wall Street

2 Outperforms
3 Underperforms
 

Players bullish on RNVS are also bullish on:

Players bearish on RNVS are also bearish on:

Ticker Tags

Biotechnology (293), Micro Cap (4824)
Suggest a tag

Renovis, Inc. At A Glance

Current Price: $2.10
Last Trade Time: 5/2/2008 4:00 PM
Open: $0.00
Previous Close: $2.10
Daily Range: $2.05 - $2.38
52-Week Range: $2.05 - $4.01
Volume: 731,870
Market Cap: $63.56M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

RNVS VS S&P 500 (SPY)

RNVS 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for RNVS

More Headlines...

Top Bull Pitch

Recs

2

Renovis, Inc. (RNVS)

Avatar drwings (< 20) Submitted: 10/24/06 4:04 PM

Stroke drug NXY-059, if it works, is likely to be $3 billion-a-year seller.

News on the drug, which was licensed in under a 15-percent royalty deal by Astro-zenica from Renovis is expected imminently because the last of more than 3,000 patients completed a pivotal Phase III clinical trial at the e...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 7 :   1 2 Next »

Recs

0

 (RNVS)

Avatar Lifeguru (66.31) Submitted: 5/16/07 9:01 PM : Underperform Start Price: $3.42 RNVS Score: 22.06

see malstryx

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (RNVS)

Avatar maverickpl (99.78) Submitted: 4/10/07 1:17 PM : Outperform Start Price: $4.55 RNVS Score: -41.87

I really don't know much about biotech besides the whole thing is a crap shoot. I keep wanting to make underperform calls on these stocks because most of them fail. Having said that, perhaps one of them will go through the roof, and it really can't hurt my score too much as an outperform. I could have picked any 4 letters, but I'm going with RNVS.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (RNVS)

Avatar polvo23 (< 20) Submitted: 2/11/07 7:58 PM : Outperform Start Price: $3.54 RNVS Score: -29.05

turn around

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (RNVS)

Avatar cramersaprentice (26.63) Submitted: 10/26/06 5:34 PM : Outperform Start Price: $3.51 RNVS Score: -31.96

this stock has been plastered and all the possible negitive news that is possible is out this one will move higher in the coming months

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (RNVS)

Avatar tonzerone (< 20) Submitted: 10/26/06 1:16 PM : Outperform Start Price: $3.81 RNVS Score: -36.47

down 75% today, at cash value, will rebound

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 7 :   1 2 Next »

Wall Street

Results 1 - 5 of 5  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackMaximGroup < 20 04/11/07 04/11/07 Outperform NS $4.46-52.91%-12.17%-40.75
TrackMatrix 90.16 10/30/06 10/30/06 Underperform NS $3.75-44.00%-7.56%+36.44
TrackBreanMurray 93.10 10/27/06 10/27/06 Underperform NS $3.51-40.17%-8.21%+31.96
TrackNeedham < 20 10/27/06 10/27/06 Underperform NS $3.51-40.17%-8.21%+31.96
TrackPiperJaff 69.84 08/22/06 08/22/06 Outperform NS $13.13-84.01%-2.15%-81.86

Results 1 - 5 of 5  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners